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a b s t r a c t
Many glycosyltransferase inhibitors in the literature are structurally derived from the donor or acceptor
substrate of the respective enzyme. A representative example is 2-naphthyl b-D-GlcNAc, a synthetic
GlcNAc glycoside that has been reported as a galactosyltransferase inhibitor. This GlcNAc derivative is
attractive as a chemical tool compound for biological and biochemical studies because of its reported
potency as an inhibitor, and its short and straightforward synthesis from readily available starting ma-
terials. We report that in our hands, 2-naphthyl b-D-GlcNAc behaved, unexpectedly, as an acceptor
substrate of the inverting b-1,4-galactosyltransferase (b-1,4-GalT) from bovine milk. This substrate ac-
tivity has not previously been described. We found that 2-naphthyl b-D-GlcNAc can be an acceptor
substrate both for recombinantly expressed b-1,4-GalT, and for a commercial batch of the same enzyme,
and both in the presence and absence of bovine serum albumin (BSA). As expected for a full acceptor
substrate, this substrate activity was time- and concentration-dependent. Additional experiments show
that the observed inhibitor/substrate switch is facilitated by a phosphatase that is an essential compo-
nent of our enzyme-coupled glycosyltransferase assay. These ﬁndings suggest that the behaviour of 2-
naphthyl b-D-GlcNAc and related acceptor-based glycosyltransferase inhibitors is strongly dependent
on the individual assay conditions. Our results therefore have important implications for the use of 2-
naphthyl b-D-GlcNAc and related glycosides as tool compounds in glycobiology and glycobiochemistry.
© 2017 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
1. Introduction
Glycosyltransferases (GTs) are key enzymes for glycan biosyn-
thesis, which catalyse the transfer of a sugar from a glycosyl donor,
e.g. a sugar-nucleotide, to a suitable acceptor [1]. GTs are involved
in many fundamental biological processes contingent on glycan
epitopes, such as cell adhesion and cancer metastasis [2,3]. GT in-
hibitors are therefore sought after as chemical tools for glycobiol-
ogy and as potential lead compounds for drug discovery [4].
An important member of the GT family is the inverting gal-
actosyltransferase b-1,4-GalT, which catalyses the transfer of D-
galactose from a UDP-a-D-galactose (UDP-Gal) donor to N-acetyl-
glucosamine (GlcNAc)-containing acceptors [5]. The resulting Galb-
1,4-GlcNAc units are found in many different glycoconjugates, and
an isoform of b-1,4-GalT has recently been identiﬁed as a major
control point for glycan branching in N-linked glycosylation [6]. b-
1,4-GalT has been used extensively as a model target for the
development of GT inhibitors, including substrate analogues based
on either donor [7,8] or acceptor [9]. Amongst the most potent
acceptor-based b-1,4-GalT inhibitors are hydrophobic GlcNAc gly-
cosides such as 2-naphthyl b-D-GlcNAc 1 (Fig. 1), for which low
micromolar inhibitory activity has been reported by Wong and co-
workers [10]. Due to the presence of the 4-OH group, in principle,1
could still behave as a substrate towards b-1,4-GalT. However, two
independent studies have described 1 as practically devoid of
acceptor substrate activity [10,11]. Similar proﬁles towards GalTs
have also been reported for other 2-naphthyl glycosides (Fig. 1)
[12,13].
For an ongoing programme on the discovery of new GT inhibitor
chemotypes, we required an established b-1,4-GalT inhibitor as a
positive control. In the absence of a commercially available b-1,4-
GalT inhibitor, we selected 2-naphthyl b-D-GlcNAc 1 because of
its potency [10] and simple, two-step synthesis [14]. The only
structural difference between 1 and the natural b-1,4-GalT acceptor
substrate GlcNAc is the presence of the naphthyl aglycon. It has
been reported that the presence of this substituent is sufﬁcient to
turn 1 from a b-1,4-GalT substrate into an inhibitor [11]. The* Corresponding author.
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inhibitory activity of 1 and several related GlcNAc derivatives has
been attributed in particular to the lipophilicity of this substituent
in the anomeric position [11].
Herein, we report that in our hands, 1 acted not as an inhibitor
but, unexpectedly, as an acceptor substrate of b-1,4-GalT. These
results are in contrast to the previously reported inhibitory activity
of this GlcNAc derivative towards b-1,4-GalT [10,11]. This substrate
activity of 1 was observed both with a batch of bovine b-1,4-GalT
recombinantly expressed in our own laboratory, and a commer-
cial batch of the same enzyme, and both in the presence and
absence of bovine serum albumin (BSA). Further experiments
revealed that this unexpected substrate activity is promoted by a
phosphatase, which is an essential component of our GT assay
mixture. Galactosylation of 1 was observed by LC/MS both in the
presence and absence of phosphatase. This proﬁle suggests that
this secondary enzyme reveals the latent acceptor substrate activity
of 1 by altering the equilibrium position of several interconnected
enzymatic reactions in the assay. This observation has important
implications for the use of 1 and related glycosides as a tool com-
pounds in glycobiology.
2. Results
2-Naphthyl b-D-GlcNAc 1 was synthesized in two steps accord-
ing to the literature procedure [14]. Nucleophilic substitution of
commercial 2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-a-D-gluco-
pyranosyl chloride 2 with 2-naphthol gave the fully acetylated
derivative 3, whichwas deprotectedwith 0.05M sodiummethoxide
Fig. 1. GalT acceptor analogues discussed in the text that have been reported as inhibitors (A) or substrates (B).
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to afford the desired 1-(2-naphthyl) 2-acetamido-2-deoxy-b-D-
glucopyranoside 1 (Scheme 1). Results from the analytical charac-
terisation of 1 by 1H- and 13C- NMR and mass spectrometry were
consistentwith data reported in the literature [14]. In particular, the
b-conﬁguration at the anomeric position was unambiguously
established based on the coupling constant between H-1 and H-2
(J ¼ 8.4 Hz). This J value is indicative of the trans orientation of H-1
and H-2, and hence the b-conﬁguration of the aglycon at the
anomeric position of 1.
Although 1 has been reported as a b-1,4-GalT inhibitor, this
monosaccharide can, in principle, also behave as a substrate to-
wards that enzyme. With sufﬁcient quantities of compound 1 in
hand, we therefore decided to ﬁrst test the potential substrate ac-
tivity of 1 towards bovine b-1,4-GalT. For these experiments, we
used a recently developed biochemical glycosyltransferase assay
[15,16]. In this coupled assay, a phosphatase is used to quantita-
tively release two equivalents of inorganic phosphate from each
molecule of UDP, the secondary product of the b-1,4-GalT reaction.
The free phosphate is then quantiﬁed colorimetrically with a mal-
achite green reagent [15,16]. For the substrate experiments, we
used 1 in place of the standard acceptor substrate GlcNAc. In initial
experiments, we evaluated the effects of acceptor concentration
and incubation time on b-1,4-GalT activity with either 1 or GlcNAc
as the acceptor substrate. Experiments with either the standard
acceptor substrate GlcNAc or the putative inhibitor 1 were con-
ducted in parallel on the same microplate. To account for the po-
tential non-speciﬁc hydrolysis of the UDP-Gal donor substrate, we
also included relevant control wells on each microplate (no
acceptor, but otherwise identical conditions). We also carried out
separate control experiments to identify potential interference of 1
with the colorimetric readout of our assay (no enzyme, but other-
wise identical conditions).
Signiﬁcant b-1,4-GalT activity was observed in both cases,
whether GlcNAc or GlcNAc derivative 1 was present as potential
acceptor substrate (Fig. 2A). The observed b-1,4-GalT activity was
dependent on the concentration of the respective acceptor. GlcNAc
derivative 1 itself does not interfere with the colorimetric readout
of our assay, as evidenced by the lack of signal in the control
experiment with increasing concentrations of 1 but without
enzyme (Fig. 2C). Interestingly, from these experiments a slightly
lower Km value can be determined for GlcNAc derivative 1 than for
GlcNAc (0.2 mM vs 1 mM), suggesting that 1may actually be a better
acceptor substrate than GlcNAc. To investigate the time de-
pendency of the b-1,4-GalTs reaction under these conditions, we
next incubated the reaction with a single concentration of GlcNAc
(5 mM) or 1 (1 mM) for 5e40 min. A clear time-dependency of
turnover was observed with both acceptors (Fig. 2D). With
increasing incubation time, UDP formation increased in the pres-
ence of both GlcNAc and 1, with a maximal turnover after 30 min.
Taken together, these results suggest strongly that, just like its
parent compound GlcNAc, GlcNAc derivative 1 is recognised as an
acceptor substrate by bovine b-1,4-GalT.
In order to understand this discrepancy with previous literature
reports [10,11], we carried out additional experiments. In the main
literature precedent, b-1,4-GalT from bovine milk was obtained
commercially, and the assay was carried out in the presence of
12.5 mg/mL BSA [11]. While BSA is frequently added to assay
mixtures to generically reduce protein adhesion to the reaction
container, in the case of GTs, a direct inﬂuence of BSA on substrate
speciﬁcity, as well as the kinetic parameters of the enzymatic re-
action, has also been observed [17]. To assess the effect of BSA on
the behaviour of GlcNAc derivative 1, we repeated the substrate
activity assay in the presence of BSA (12.5 mg/mL). Assay mixtures
were incubated for 20min and absorbancewas recorded at 620 nm.
When the formation of UDP was plotted over the concentration of
acceptor (GlcNAc or 1), once again very similar reaction proﬁles
were observed for both GlcNAc and GlcNAc derivative 1 (Fig. 2B).
The absence of BSA from our initial experiments could therefore be
ruled out as a potential explanation for the observed discrepancy
with the previous literature results. Interestingly, the turnover rates
for both GlcNAc and 1were higher in the presence of BSA than in its
absence (Fig. 2B). This effect of BSA is in keeping with observations
for another glycosyltransferase [17].
While our initial experiments were all carried out with a batch
of bovine b-1,4-GalT recombinantly expressed in our own labora-
tory, previously reported results for 1 were obtained with a
commercially available enzyme [11]. The information provided by
the supplier about this b-1,4-GalT is limited, and it was therefore
not certain if it was identical to our own recombinant batch. We
therefore decided to repeat our experiments with a batch of com-
mercial b-1,4-GalT from the same supplier. First, we determined the
activity of the commercial b-1,4-GalT as 12.7 mU/mL (ESI). Then, we
repeated the substrate assayswith either GlcNAc or 1 as acceptor, in
the absence or presence of BSA. The results were practically iden-
tical to those obtained previously with recombinantly expressed
enzyme. GlcNAc derivative 1 once again acted as a substrate to-
wards b-1,4-GalT, both in the absence and presence of BSA (Fig. S1).
In the presence of BSA, turnover rates increased approximately 2-
fold, for both GlcNAc and 1. The Km value of each substrate also
increased, by approximately 4-fold (GlcNAc: 0.4 mM without BSA,
1.5 mM with BSA; 1: 0.08 mM without BSA, 0.3 mM with BSA). Most
importantly, both trends (increased turnover, increased Km) are
practically identical for both GlcNAc and GlcNAc derivative 1. This
provides further evidence that both monosaccharides can serve, in
an identical manner, as acceptor substrates for b-1,4-GalT.
Our standard assay does not detect the primary product of the
GalT reaction, in contrast to the radiochemical GT assay used in the
original reports of 1 as a b-1,4-GalT inhibitor [10,11]. In order to
directly detect the putative galactosylation product of 1, we
therefore carried out LC/MS experiments. 1 (500 mМ), recombinant
b-1,4-GalT (200 mL) and UDP-Gal (500 mМ) were incubated for 1 h at
30 C in HEPES buffer (pH 7.0, 50 mM KCl). Analysis of the reaction
by LC/MS showed the appearance of a new peak in the chromato-
gram, at a slightly shorter retention time than the peak corre-
sponding to 1 (Fig. S2). While the separation of the two peaks is not
complete, the mass spectra conﬁrmed the formation of a species
Scheme 1. Synthesis of 2-naphthyl b-D-GlcNAc 1 [14].
Reagents and conditions: (i) tetrabutylammonium bromide, 1N NaOH, DCM, rt, 2 h; (b) NaOMe, MeOH/toluene (1:1), rt, 0.5 h.
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with a molecular ion of 532, which corresponds to the sodium
adduct of mono-galactosylated 1, Gal-1. This result provides direct
evidence that 1 can indeed act as an acceptor substrate for b-1,4-
GalT. The formation of Gal-1 was strongly dependent on the
amount of b-1,4-GalT present, and signiﬁcant levels of the gal-
actosylated species were only observed at the highest enzyme
concentration tested (Fig. S3, A-C). Interestingly, however, if
phosphatase (20 mL) was present in the reaction mixture, similar
levels of Gal-1 were observed even at a lower b-1,4-GalT concen-
tration (Fig. S3, D). The conditions used for this last experiment are
identical to the ones used in our standard assay protocol. These
results therefore suggest that the enzymatic proﬁles which we
observed in our biochemical assays were indeed due to the
behaviour of 1 as an acceptor substrate of b-1,4-GalT.
3. Discussion
Building on the seminal work by Lemieux [18], Palcic has pre-
viously shown that GlcNAc glycosides with a hydrophobic aglycon,
such as 8-methoxycarbonyloctyl GlcNAc and 4-methylumbelliferyl
GlcNAc (Fig. 1), are highly effective acceptor substrates for b-1,4-
GalT [19]. Intriguingly, the closely related GlcNAc derivative 1 has
been reported in two separate studies as an inhibitor, but not a
substrate, of b-1,4-GalT [10,11]. In our hands, however,1 did behave
as an acceptor substrate towards this enzyme, with a similar proﬁle
as the natural GlcNAc acceptor. This discrepancy is not due to a case
of “mistaken identity” of 1. Spectroscopic characterisation of our
batch of 1 and careful comparisonwith literature data [14] conﬁrms
that the compound used in this study is identical to the one that
had been reported previously.
Fig. 2. Acceptor substrate assays with GlcNAc or 1, and recombinant b-1,4-GalT.
Conditions: All experiments were carried out in triplicate. Bars indicate mean values ± S.D. A b-1,4-GalT, GlcNAc (0e5 mM) or 1 (0e1 mM), UDP-Gal donor (28 mM), MnCl2 (5 mM),
chicken egg-white lysozyme (1 mg/mL), calf-intestinal phosphatase (10 U/mL), DMSO (10%) and buffer (13 mM HEPES, pH 7.0, 50 mM KCl) were incubated in a 96-well plate at 30 C
with shaking for 20 min. The reaction was stopped by the addition of malachite reagents, and the absorbance was recorded at 620 nm after 30 min. B Conditions as in A but with
bovine serum albumin (1.25 mg/mL). C Conditions as in A with compound 1 (0e1 mM) as the substrate, but without b-1,4-GalT. D Conditions as in A, with GlcNAc (5 mM) or 1
(1 mM) as the acceptor, and with incubation times from 5 to 40 min.
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Our results suggest that the behaviour of 1 towards b-1,4-GalT is
strongly dependent on the assay conditions. In the literature pre-
cedent, GlcNAc derivative 1 and its analogues were tested in a
radiochemical GT assay, which directly detects the galactosylated
reaction product [11]. The enzyme-coupled assay used in the pre-
sent study requires a phosphatase, in conjunction with a colori-
metric read-out, to measure the formation of UDP, the secondary
product of the b-1,4-GalT reaction [16]. We have eliminated po-
tential false positives that would speciﬁcally affect our assay pro-
tocol, e.g. from non-speciﬁc hydrolysis of UDP, by including the
requisite control experiments. We have also investigated the role of
speciﬁc assay components used in the original assay, such as BSA,
and the source of the b-1,4-GalT. We found that these parameters
do not fundamentally alter the outcome of the reaction. These re-
sults demonstrate that despite the different assay formats, the re-
sults from the radiochemical assay used in the previous study, and
from our own colorimetric assay are, in principle, comparable.
Despite the seeming contradiction, our ﬁndings are not irrec-
oncilable with the previous results. We have observed substrate
activity for 1 both in the presence and absence of phosphatase. This
suggests that while the presence of the phosphatase in our assay
facilitates the utilisation of 1 as a b-1,4-GalT acceptor substrate, it is
not essential. The addition of phosphatase or NDP-cycling enzymes
is a well-established approach in chemo-enzymatic applications of
GTs, to drive the GT reaction to completion and to improve the
efﬁciency of the overall synthetic process [20]. It is likely that the
presence of the phosphatase in our assay affects the equilibrium
between different species along the b-1,4-GalT kinetic pathway in a
similar fashion.
We propose the following model, which is consistent with both
our own data and the previous ﬁndings (Fig. 3): because of its close
structural similarity to the natural acceptor GlcNAc,1 can indeed be
recognised as an acceptor substrate by b-1,4-GalT, which converts it
into the corresponding disaccharide Gal-1. This disaccharide may
form a stable, non-covalent complex with the enzyme, acting
effectively as a feedback inhibitor. This would be consistent with
the previous ﬁnding that a hydrophobic aglycone such as 2-napthyl
is crucial for strong substrate binding in this series [11]. This
inhibitory effect can be overcome either by increasing the con-
centration of b-1,4-GalT, or by including phosphatase in the assay
mixture. The irreversible, phosphatase-catalysed hydrolysis of UDP
will shift the overall equilibrium towards the reaction products,
thus revealing the latent substrate activity of 1 even at low b-1,4-
GalT concentrations (Fig. 3). It has to be emphasised that at pre-
sent, this model is hypothetical. Its deﬁnitive test will require the
synthesis and testing of the Gal-1 disaccharide. While disaccharide
product inhibition of glycosyltransferases is perhaps less common
than inhibition by the NDP reaction product, there is precedent for
the inhibition of b-1,4-GalT by disaccharide acceptor analogues
[21].
4. Conclusion
In conclusion, we have found that 2-naphthyl b-D-GlcNAc 1 can
behave as an acceptor substrate towards b-1,4-GalTs from bovine
milk. This substrate activity has not previously been described. Its
discovery was facilitated by the presence of a phosphatase in our
enzyme-coupled GT assay, which affects the reaction equilibria
along the b-1,4-GalT kinetic pathway. The ﬁnding that 1 can behave
as a b-1,4-GalT substrate has implications both for the design and
the application of acceptor-based GT inhibitors: in principle, 1 and
related GT inhibitors are attractive chemical tools to study glyco-
sylation in cells. Our results suggest that such applications in cells
may be complicated by the presence of phosphatases, which will
very likely modulate the inhibitor/substrate behaviour of such
acceptor analogues. Following conversion of 1 into the corre-
sponding disaccharide, it may be this disaccharide that acts as the
actual inhibitory species through a feedback inhibition mechanism.
In this case, the substrate activity of 1would be a prerequisite for its
inhibitory activity. Given the considerable number of acceptor-
based GT inhibitors in the literature, these questions warrant
further investigation. The present study provides a starting point
for such investigations.
5. Experimental section
General. All reagents were obtained commercially and used as
received unless stated otherwise. GlcNAc derivative 1 was synthe-
sized as previously reported and characterised by 1H- and 13C-NMR
spectroscopy and mass spectrometry [14]. Thin-layer chromatog-
raphy (TLC) was performed on pre-coated aluminium plates (Silica
Gel 60 F254, Merck) and compounds were visualised by exposure to
UV light (254 and 280 nm). Preparative chromatography was car-
ried out on silica gel 60 (pore size 60 Å, 230e400 mesh, Sigma-
Aldrich) at normal pressure. NMR spectra were recorded at 298K
on a Bruker Avance DRX 400 spectrometer (400 MHz for 1H,
100 MHz for 13C). Chemical shifts (d) are reported in ppm (parts per
million). Coupling constants (J) are reported in Hz.
2-Naphthyl 3,4,6-tri-O-acetyl 2-acetamido-2-deoxy-b-D-glu-
copyranoside (3) [14]. To an aqueous solution of sodium hydroxide
(1M, 2 mL), a solution of 3,4,6-tri-O-acetyl-2-deoxy-a-D-gluco-
pyranosyl chloride 2 (400 mg, 1 equiv.), 2-naphthol (319 mg, 2
equiv.) and tetra-n-butylammonium bromide (354 mg, 1 equiv.) in
methylene chloride (2 mL) was added. The resulting two-phase
D E
A
+ D E D EA D* EA*
D* EA*+ +
phosphatase
stable complex of primary 
products and GalT:
uridine + Pi
irreversible formation of 
secondary products:
inhibitory activity
predominates
substrate activity
predominates
Fig. 3. Hypothetical model for the dual activity of 1 as either acceptor substrate or inhibitor along the b-1,4-GalT kinetic pathway (D: donor sugar-nucleotide, E: enzyme, A:
acceptor, A*: galactosylated acceptor, D*: nucleoside diphosphate).
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systemwas stirred for 2 h at rt. The mixture was diluted with ethyl
acetate and the organic phasewashed sequentially with an aqueous
solution of 1M sodium hydroxide and water, then dried. The
organic extract was then ﬁltered, and the ﬁltrate concentrated to
yield a crude solid which was puriﬁed by chromatography (DCM/
MeOH 20:1), to yield 389 mg of a white powder (75%). 1H-NMR
(400 MHz, CDCl3): d 7.81 (d, 2H, J ¼ 9.0 Hz, H-4 and H-9 of naph-
thyl), 7.77 (d, 1H, J ¼ 8.0 Hz, H-6 of naphthyl), 7.47 (m, 1H, H-7 of
naphthyl), 7.44 (d, 1H, J¼ 2.5 Hz, H-1 of naphthyl), 7.38 (m, 2H, H-8,
H-5 of naphthyl), 7.22 (dd, 1H, J¼ 2.5, 9.0 Hz, H-3 of naphthyl), 5.46
(d, 1H, J¼ 8.0 Hz, H-1), 5.39 (dd, 1H, J ¼ 10.5, 10.5 Hz, H-3), 5.11 (dd,
1H, J ¼ 10.5, 10.5 Hz, H-4), 4.36 (dd, 1H, J ¼ 5.5, 12.5 Hz, H-6), 4.16
(M, 2H, H-2 and H-6), 4.11 (m, 1H, H-5), 2.07, 2.06, 2.04 (3  s, 9H,
acetyl), 1.96 (s, 3H, acetamido). 13C-NMR (100 MHz, CDCl3): d 20.8,
20.9, 20.9, 23.3, 59.0, 61.9, 71.0, 74.6, 78.0, 82.3, 121.0, 126.1, 126.5,
127.9, 128.0, 130.3, 137.4, 128.5, 148.1, 156.9, 170.4,171.4, 171.8, 172.5.
1-(2-Naphthyl) 2-acetamido-2-deoxy-b-D-glucopyranoside
(1) [14]. To a solution of 3 (200 mg) in methanol-toluene (1:1) was
added a catalytic amount of 0.5M sodium methoxide in methanol.
The reaction mixture was stirred at room temperature for 0.5 h and
the progress of the reaction was monitored by TLC (DCM/MeOH
4:1). Upon completion of the reaction, the organic solution was
concentrated, and the residue was puriﬁed by chromatography
(DCM/MeOH 4:1), to yield 92 mg of a white powder (88%). 1H-NMR
(400 MHz, MeOD): d 7.76 (m, 3H, H-4, H-9, H-6 of naphthyl), 7.42
(m, 2H, H-7, H-1 of naphthyl), 7.34 (m, 1H, H-8 of naphthyl), 7.18
(dd,1H, J¼ 2.4, 9.2 Hz, H-3 of naphthyl), 5.19 (d,1H, J¼ 8.4 Hz, H-1),
4.00 (dd, 1H, J ¼ 8.4, 10.4Hz, H-2), 3.98 (dd, 1H, J ¼ 2.4, 12Hz, H-6),
3.77 (1H, dd, J ¼ 5.6, 12Hz, H-6), 3.63 (dd, 1H, J ¼ 8.4, 10Hz, H-3),
3.58 (m, 1H, H-5), 3.48 (dd, 1H, J ¼ 8.8, 9.6Hz, H-4), 1.99 (s, 3H,
NHCH3). 13C-NMR (100 MHz, MeOD): d 23.0, 57.4, 62.6, 71.9, 75.9,
78.4, 101.0, 111.9, 119.8, 125.3, 127.4, 128.2, 128.6, 130.4, 131.3, 135.9,
156.9, 174.0. m/z (ESI) 371.1199 [M þ H þ Na]2þ, C18H22NNaO6 re-
quires 371.1345.
Enzymology. The plasmid for b-1,4-GalT from bovinemilk was a
generous gift from Dr Christelle Breton (Grenoble). Bovine b-1,4-
GalT was either expressed in our own laboratory as previously re-
ported [7] or obtained commercially (Sigma). For the biochemical
assays, we used a recently reported colorimetric protocol [16]. All
assays were carried out in Nunc clear, ﬂat-bottom 96-well poly-
styrene microplates. Assay wells typically contained MnCl2, calf-
intestinal phosphatase (CIP), chicken egg-white lysozyme (CEL),
UDP-Gal donor and either GlcNAc or 1 as acceptor (for details of the
assay protocol see ESI). To quantify the concentration of inorganic
phosphate (Pi), malachite green reagents were added, and the
absorbance was recorded at 620 nm on a BMG Labtech POLARstar
Optima multiplate reader.
Data collection and analysis. A calibration curve (0e12.5 mM
UDP, corresponding to 0e25 mM Pi) was constructed for each
microplate by linear regression. The calibration curve was used to
convert absorbance measurements at 620 nm in sample and con-
trol wells to [UDP] (mM). For each sample and control well, a cor-
responding background well (containing identical components but
no acceptor) was included, to account for non-speciﬁc hydrolysis of
donor. Corrected absorbance values for each well were obtained by
subtracting the corresponding background reading from the
absorbance of the respective sample or control well. The calculated
concentration of UDPwas plotted against concentration of acceptor
(for substrate assay or control assay) or incubation time (for time-
dependent assays). Averages and standard deviations were calcu-
lated in Microsoft Excel.
6. LC/MS experiments
Standard assay mixtures for investigating the acceptor proper-
ties of compound 1 towards b-1,4-GalT contained UDP-Gal (500
mМ), compound 1 (500 mМ), b-1,4-GalT (20, 50 or 200 mL, Fig. S3),
calf intestinal phosphatase (20 mL, assay D only, Fig. S3), 13 mM
HEPES buffer (pH 7.0, 50 mM KCl). Mixtures were incubated for 1 h
at 30 C in a water bath. Reactions were stopped by the addition of
the same volume of methanol. The mixtures were centrifuged for
15min at 1000 rpm. The supernatants were used for LC/MS analysis
directly. LC/MS analysis was carried out on an HPLC reverse phase
column (Agilent Eclipse XDB-C8 4.6  150 mm) with water (0.1%
formic acid) against methanol as the mobile phase. The gradient is
shown in Table 1. The HPLC was coupled to an Advion Compact
Mass Spectrometer (CMS) for mass detection.
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